Mutant tubulins may help reduce tau-related damage in Alzheimer's disease.
Mutant Tubulins Confer Resistance to Pathological Tau
This study is looking at how certain changes in tubulin proteins might help protect brain cells from damage caused by tau, a protein linked to Alzheimer's and similar diseases, using tiny worms and brain cells to find new ways to treat these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Inst for Biomedical/clinical Res NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11042274 on NIH RePORTER |
What this research studies
This research investigates how mutant tubulin proteins can influence the effects of pathological tau, a protein associated with Alzheimer's disease and other neurodegenerative conditions. By using model organisms like C. elegans and mammalian neurons, the study aims to understand how these mutations can alter the interactions between tau and microtubules, potentially reducing neurodegeneration. The research employs a combination of genetic manipulation, in vitro systems, and cellular assays to explore these mechanisms. The ultimate goal is to uncover new insights that could lead to effective treatments for tauopathies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease or related tauopathies.
Not a fit: Patients with tauopathies not related to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating Alzheimer's disease and other tau-related disorders.
How similar studies have performed: While the approach of using mutant tubulins is innovative, similar studies have shown promise in understanding tau-related mechanisms, indicating potential for success.
Where this research is happening
Seattle, United States
- Seattle Inst for Biomedical/clinical Res — Seattle, United States (Active)
Researchers
- Principal investigator: Benbow, Sarah Jean Zimmerman — Seattle Inst for Biomedical/clinical Res
- Study coordinator: Benbow, Sarah Jean Zimmerman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.